;PMID: 8490873
;source_file_2876.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..142] = [t:47..142]
;2)section:[e:146..156] = [t:146..156]
;3)section:[e:160..225] = [t:160..225]
;4)sentence:[e:229..306] = [t:229..306]
;5)sentence:[e:308..515] = [t:308..515]
;6)sentence:[e:516..688] = [t:516..688]
;7)sentence:[e:689..1015] = [t:689..1015]
;8)sentence:[e:1016..1351] = [t:1016..1351]
;9)section:[e:1355..1399] = [t:1355..1399]

;section 0 Span:0..41
;Cancer.  1993 May 15;71(10 Suppl):3310-3.
(SEC
  (FRAG (NNP:[0..6] Cancer) (,:[6..7] .) (CD:[9..13] 1993) (NNP:[14..17] May)
        (CD:[18..20] 15) (::[20..21] ;) (CD:[21..23] 71) (-LRB-:[23..24] -LRB-)
        (CD:[24..26] 10) (NN:[27..32] Suppl) (-RRB-:[32..33] -RRB-)
        (::[33..34] :) (CD:[34..40] 3310-3) (.:[40..41] .)))

;sentence 1 Span:47..142
;Disordered differentiation as a target for novel approaches to the treatment
;of  neuroblastoma.
;[128..141]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP (VBN:[47..57] Disordered) (NN:[58..73] differentiation))
    (PP (IN:[74..76] as)
      (NP
        (NP (DT:[77..78] a) (NN:[79..85] target))
        (PP (IN:[86..89] for)
          (NP
            (NP (JJ:[90..95] novel) (NNS:[96..106] approaches))
            (PP (TO:[107..109] to)
              (NP
                (NP (DT:[110..113] the) (NN:[114..123] treatment))
                (PP (IN:[124..126] of)
                  (NP (NN:[128..141] neuroblastoma)))))))))
    (.:[141..142] .)))

;section 2 Span:146..156
;Israel MA.
(SEC
  (FRAG (NNP:[146..152] Israel) (NNP:[153..155] MA) (.:[155..156] .)))

;section 3 Span:160..225
;Pediatrics Branch, National Cancer Institute, Bethesda, Maryland.
(SEC
  (FRAG (NNP:[160..170] Pediatrics) (NNP:[171..177] Branch) (,:[177..178] ,)
        (NNP:[179..187] National) (NNP:[188..194] Cancer)
        (NNP:[195..204] Institute) (,:[204..205] ,) (NNP:[206..214] Bethesda)
        (,:[214..215] ,) (NNP:[216..224] Maryland) (.:[224..225] .)))

;sentence 4 Span:229..306
;Some childhood malignant neoplasms are thought to arise in embryonic
;tissues.
;[234..243]:malignancy-developmental-state:"childhood"
;[244..253]:malignancy-clinical-stage:"malignant"
;[254..263]:malignancy-type:"neoplasms"
;[288..297]:malignancy-developmental-state:"embryonic"
(SENT
  (S
    (NP-SBJ-1 (DT:[229..233] Some) (NN:[234..243] childhood)
              (JJ:[244..253] malignant) (NNS:[254..263] neoplasms))
    (VP (VBP:[264..267] are)
      (VP (VBN:[268..275] thought)
        (S
          (NP-SBJ-1 (-NONE-:[275..275] *))
          (VP (TO:[276..278] to)
            (VP (VB:[279..284] arise)
              (PP-LOC (IN:[285..287] in)
                (NP (JJ:[288..297] embryonic) (NNS:[298..305] tissues))))))))
    (.:[305..306] .)))

;sentence 5 Span:308..515
;These tumors present unique opportunities for studying the maturation of 
;specific cellular lineages and examining the possible role of alterations in
;the  regulation of differentiation in tumor development.
(SENT
  (S
    (NP-SBJ (DT:[308..313] These) (NNS:[314..320] tumors))
    (VP (VBP:[321..328] present)
      (NP
        (NP (JJ:[329..335] unique) (NNS:[336..349] opportunities))
        (PP (IN:[350..353] for)
          (S-NOM
            (NP-SBJ (-NONE-:[353..353] *))
            (VP
              (VP (VBG:[354..362] studying)
                (NP
                  (NP (DT:[363..366] the) (NN:[367..377] maturation))
                  (PP (IN:[378..380] of)
                    (NP (JJ:[382..390] specific) (JJ:[391..399] cellular)
                        (NNS:[400..408] lineages)))))
              (CC:[409..412] and)
              (VP (VBG:[413..422] examining)
                (NP
                  (NP (DT:[423..426] the) (JJ:[427..435] possible)
                      (NN:[436..440] role))
                  (PP (IN:[441..443] of)
                    (NP
                      (NP (NNS:[444..455] alterations))
                      (PP (IN:[456..458] in)
                        (NP
                          (NP (DT:[459..462] the) (NN:[464..474] regulation))
                          (PP (IN:[475..477] of)
                            (NP (NN:[478..493] differentiation)))))))
                  (PP (IN:[494..496] in)
                    (NP (NN:[497..502] tumor) (NN:[503..514] development))))))))))
    (.:[514..515] .)))

;sentence 6 Span:516..688
;Several features of  neuroblastoma, a tumor thought to arise in cells
;originating in the embryonic  neural crest, suggest that it may be
;particularly useful in this regard.
;[537..550]:malignancy-type:"neuroblastoma"
;[605..614]:malignancy-developmental-state:"embryonic"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (JJ:[516..523] Several) (NNS:[524..532] features))
        (PP (IN:[533..535] of)
          (NP (NN:[537..550] neuroblastoma))))
      (,:[550..551] ,)
      (NP
        (NP (DT:[552..553] a) (NN:[554..559] tumor))
        (VP (VBN:[560..567] thought)
          (S
            (NP-SBJ (-NONE-:[567..567] *))
            (VP (TO:[568..570] to)
              (VP (VB:[571..576] arise)
                (PP-LOC (IN:[577..579] in)
                  (NP
                    (NP (NNS:[580..585] cells))
                    (VP (VBG:[586..597] originating)
                      (PP-LOC (IN:[598..600] in)
                        (NP (DT:[601..604] the) (JJ:[605..614] embryonic)
                            (JJ:[616..622] neural) (NN:[623..628] crest))))))))))))
    (,:[628..629] ,)
    (VP (VBP:[630..637] suggest)
      (SBAR (IN:[638..642] that)
        (S
          (NP-SBJ (PRP:[643..645] it))
          (VP (MD:[646..649] may)
            (VP (VB:[650..652] be)
              (ADJP-PRD (RB:[653..665] particularly) (JJ:[666..672] useful))
              (PP (IN:[673..675] in)
                (NP (DT:[676..680] this) (NN:[681..687] regard))))))))
    (.:[687..688] .)))

;sentence 7 Span:689..1015
;The  identification of a series of markers that characterize the various cell
;types  of the peripheral nervous system that are detectable in neuroblastoma
;tumor  tissues has made it possible to recognize that the cells of
;neuroblastoma tumor  cell lines and tissues correspond to specific stages of
;adrenal gland  development.
;[830..843]:malignancy-type:"neuroblastoma"
;[911..930]:malignancy-type:"neuroblastoma tumor"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[689..692] The) (NN:[694..708] identification))
      (PP (IN:[709..711] of)
        (NP
          (NP (DT:[712..713] a) (NN:[714..720] series))
          (PP (IN:[721..723] of)
            (NP
              (NP
                (NP (NNS:[724..731] markers))
                (SBAR
                  (WHNP-2 (WDT:[732..736] that))
                  (S
                    (NP-SBJ-2 (-NONE-:[736..736] *T*))
                    (VP (VBP:[737..749] characterize)
                      (NP
                        (NP (DT:[750..753] the) (JJ:[754..761] various)
                            (NN:[762..766] cell) (NNS:[767..772] types))
                        (PP (IN:[774..776] of)
                          (NP (DT:[777..780] the) (JJ:[781..791] peripheral)
                              (JJ:[792..799] nervous) (NN:[800..806] system))))))))
              (SBAR
                (WHNP-3 (WDT:[807..811] that))
                (S
                  (NP-SBJ-3 (-NONE-:[811..811] *T*))
                  (VP (VBP:[812..815] are)
                    (ADJP-PRD (JJ:[816..826] detectable))
                    (PP-LOC (IN:[827..829] in)
                      (NP (NN:[830..843] neuroblastoma) (NN:[844..849] tumor)
                          (NNS:[851..858] tissues)))))))))))
    (VP (VBZ:[859..862] has)
      (VP (VBN:[863..867] made)
        (S
          (NP-SBJ (PRP:[868..870] it))
          (ADJP-PRD (JJ:[871..879] possible)
            (S
              (NP-SBJ (-NONE-:[879..879] *))
              (VP (TO:[880..882] to)
                (VP (VB:[883..892] recognize)
                  (SBAR (IN:[893..897] that)
                    (S
                      (NP-SBJ
                        (NP (DT:[898..901] the) (NNS:[902..907] cells))
                        (PP (IN:[908..910] of)
                          (NP
                            (NP
                              (NML-1 (NN:[911..924] neuroblastoma)
                                     (NN:[925..930] tumor))
                              (NN:[932..936] cell) (NNS:[937..942] lines))
                            (CC:[943..946] and)
                            (NP
                              (NML-1 (-NONE-:[946..946] *P*))
                              (NNS:[947..954] tissues)))))
                      (VP (VBP:[955..965] correspond)
                        (PP-CLR (TO:[966..968] to)
                          (NP
                            (NP (JJ:[969..977] specific) (NNS:[978..984] stages))
                            (PP (IN:[985..987] of)
                              (NP (JJ:[988..995] adrenal) (NN:[996..1001] gland)
                                  (NN:[1003..1014] development)))))))))))))))
    (.:[1014..1015] .)))

;sentence 8 Span:1016..1351
;Experiments directed at understanding the cellular signals by which  neural
;crest cell maturation is mediated may provide insights of therapeutic  import
;because neuroblastoma tumors corresponding to some stages of  differentiation
;respond very differently to nonspecific cytotoxic therapies than  tumors
;corresponding to other stages.
;[1178..1198]:malignancy-type:"neuroblastoma tumors"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1016..1027] Experiments))
      (VP (VBN:[1028..1036] directed)
        (NP (-NONE-:[1036..1036] *))
        (PP (IN:[1037..1039] at)
          (S-NOM
            (NP-SBJ (-NONE-:[1039..1039] *))
            (VP (VBG:[1040..1053] understanding)
              (NP
                (NP (DT:[1054..1057] the) (JJ:[1058..1066] cellular)
                    (NNS:[1067..1074] signals))
                (SBAR
                  (WHPP-2 (IN:[1075..1077] by)
                    (WHNP (WDT:[1078..1083] which)))
                  (S
                    (NP-SBJ-1 (JJ:[1085..1091] neural) (NN:[1092..1097] crest)
                              (NN:[1098..1102] cell)
                              (NN:[1103..1113] maturation))
                    (VP (VBZ:[1114..1116] is)
                      (VP (VBN:[1117..1125] mediated)
                        (NP-1 (-NONE-:[1125..1125] *))
                        (PP-MNR-2 (-NONE-:[1125..1125] *T*))))))))))))
    (VP (MD:[1126..1129] may)
      (VP (VB:[1130..1137] provide)
        (NP
          (NP (NNS:[1138..1146] insights))
          (PP (IN:[1147..1149] of)
            (NP (JJ:[1150..1161] therapeutic) (NN:[1163..1169] import))))
        (SBAR-PRP (IN:[1170..1177] because)
          (S
            (NP-SBJ
              (NP (NN:[1178..1191] neuroblastoma) (NNS:[1192..1198] tumors))
              (VP (VBG:[1199..1212] corresponding)
                (PP-CLR (TO:[1213..1215] to)
                  (NP
                    (NP (DT:[1216..1220] some) (NNS:[1221..1227] stages))
                    (PP (IN:[1228..1230] of)
                      (NP (NN:[1232..1247] differentiation)))))))
            (VP (VBP:[1248..1255] respond)
              (ADVP (RB:[1256..1260] very) (RB:[1261..1272] differently))
              (PP-CLR (TO:[1273..1275] to)
                (NP (JJ:[1276..1287] nonspecific) (JJ:[1288..1297] cytotoxic)
                    (NNS:[1298..1307] therapies)))
              (PP (IN:[1308..1312] than)
                (NP
                  (NP (NNS:[1314..1320] tumors))
                  (VP (VBG:[1321..1334] corresponding)
                    (PP-CLR (TO:[1335..1337] to)
                      (NP (JJ:[1338..1343] other) (NNS:[1344..1350] stages)))))))))))
    (.:[1350..1351] .)))

;section 9 Span:1355..1399
;PMID: 8490873 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1355..1359] PMID) (::[1359..1360] :) (CD:[1361..1368] 8490873)
        (NN:[1369..1370] -LSB-) (NNP:[1370..1376] PubMed) (::[1377..1378] -)
        (NN:[1379..1386] indexed) (IN:[1387..1390] for)
        (NNP:[1391..1398] MEDLINE) (-RRB-:[1398..1399] -RSB-)))
